HHS Must End Unauthorized Administration Of 340B Drug-Discount Program [Forbes]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Forbes
This past September, a sub-agency of the Department of Health and Human Services (HHS) threatened to kick a pharmaceutical company out of Medicare because the company, in line with federal law, offered a healthcare provider discounts on two of its drugs. This unprecedented turn of events is but the latest example of the Health Resources and Service Administration's (HRSA) distortion of Public Health Service Act § 340B and the agency's broader statutory overreach. The incoming administration would do public health, and especially low-income patients, a true service by recalibrating HRSA's administration of the 340B program. 340B Background Section 340B imposes only two requirements on pharmaceutical manufacturers. If they wish to sell their drugs to the federal government, drug makers must offer certain healthcare providers the opportunity to purchase drugs at or below a price ceiling that is set out in a pricing agreement. The providers, or “covered entities,” service low-income
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaGlobeNewswire
- Neuraxpharm reports another year of sustained growth and international expansion [Yahoo! Finance]Yahoo! Finance
- Diabetics left without treatment as global rate of disease doubles [Financial Times (FT.com) (UK)]Financial Times
- BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition [Yahoo! Finance]Yahoo! Finance
- Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight [Yahoo! Finance]Yahoo! Finance
SNY
Analyst Actions
- 9/19/24 - Citigroup Inc.
SNY
Sec Filings
- 11/7/24 - Form SC
- 11/7/24 - Form 6-K
- 10/31/24 - Form 6-K
- SNY's page on the SEC website